S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
A.I. ETF Sold Out Of Monster Energy, Three Ways To Look At It
Graphite versus Lithium - What Investors Should Know (Ad)
Stock market today: Wall Street futures point higher on debt deal, but some tremors in retail
The Most Upgraded Stocks From The Q1 Earnings Season
AI is Unstoppable. Now Is The Time! (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
AI is Unstoppable. Now Is The Time! (Ad)
Is This The Collapse of Icahn Enterprises ?
What Does the Airbnb Guidance Drop Say About Travel Demand?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
A.I. ETF Sold Out Of Monster Energy, Three Ways To Look At It
Graphite versus Lithium - What Investors Should Know (Ad)
Stock market today: Wall Street futures point higher on debt deal, but some tremors in retail
The Most Upgraded Stocks From The Q1 Earnings Season
AI is Unstoppable. Now Is The Time! (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
AI is Unstoppable. Now Is The Time! (Ad)
Is This The Collapse of Icahn Enterprises ?
What Does the Airbnb Guidance Drop Say About Travel Demand?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
A.I. ETF Sold Out Of Monster Energy, Three Ways To Look At It
Graphite versus Lithium - What Investors Should Know (Ad)
Stock market today: Wall Street futures point higher on debt deal, but some tremors in retail
The Most Upgraded Stocks From The Q1 Earnings Season
AI is Unstoppable. Now Is The Time! (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
AI is Unstoppable. Now Is The Time! (Ad)
Is This The Collapse of Icahn Enterprises ?
What Does the Airbnb Guidance Drop Say About Travel Demand?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
A.I. ETF Sold Out Of Monster Energy, Three Ways To Look At It
Graphite versus Lithium - What Investors Should Know (Ad)
Stock market today: Wall Street futures point higher on debt deal, but some tremors in retail
The Most Upgraded Stocks From The Q1 Earnings Season
AI is Unstoppable. Now Is The Time! (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
AI is Unstoppable. Now Is The Time! (Ad)
Is This The Collapse of Icahn Enterprises ?
What Does the Airbnb Guidance Drop Say About Travel Demand?
NASDAQ:HZNP

Horizon Therapeutics Public (HZNP) Stock Forecast, Price & News

$100.03
+0.68 (+0.68%)
(As of 05/31/2023 ET)
Compare
Today's Range
$99.27
$100.76
50-Day Range
$96.34
$112.38
52-Week Range
$57.84
$113.83
Volume
2.98 million shs
Average Volume
3.41 million shs
Market Capitalization
$22.87 billion
P/E Ratio
62.91
Dividend Yield
N/A
Price Target
$111.42

Horizon Therapeutics Public MarketRank™ Forecast

Analyst Rating
Hold
2.27 Rating Score
Upside/​Downside
11.4% Upside
$111.42 Price Target
Short Interest
Healthy
3.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
0.35mentions of Horizon Therapeutics Public in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
38.05%
From $4.81 to $6.64 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

268th out of 1,006 stocks

Pharmaceutical Preparations Industry

124th out of 492 stocks


HZNP stock logo

About Horizon Therapeutics Public (NASDAQ:HZNP) Stock

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Receive HZNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter.

HZNP Stock News Headlines

3 Stocks Worth Buying at 52-Week Lows (HZNP)
Here are three stocks that are trading near their 52-week lows and may be primed for a short-term rally for opportunistic investors
Graphite versus Lithium - What Investors Should Know
Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.
Graphite versus Lithium - What Investors Should Know
Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.
Jefferies Sticks to Its Buy Rating for Horizon Therapeutics (HZNP)
Pre-market Movers: GDC, ELOX, VOXX, HZNP, CALT…
Why Amgen Stock Was Sickly Today
See More Headlines
Receive HZNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter.

HZNP Company Calendar

Last Earnings
5/03/2023
Today
5/31/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:HZNP
CUSIP
44047T10
Employees
2,115
Year Founded
2008

Price Target and Rating

Average Stock Price Forecast
$111.42
High Stock Price Forecast
$144.00
Low Stock Price Forecast
$71.00
Forecasted Upside/Downside
+11.4%
Consensus Rating
Hold
Rating Score (0-4)
2.27
Research Coverage
11 Analysts

Profitability

Net Income
$521.48 million
Pretax Margin
10.44%

Debt

Sales & Book Value

Annual Sales
$3.63 billion
Cash Flow
$7.08 per share
Book Value
$22.29 per share

Miscellaneous

Free Float
222,906,000
Market Cap
$22.87 billion
Optionable
Optionable
Beta
1.13

Social Links


Key Executives

  • Timothy P. WalbertTimothy P. Walbert
    Chairman, President & Chief Executive Officer
  • Aaron L. Cox
    Chief Financial Officer & Executive Vice President
  • Jeffrey W. ShermanJeffrey W. Sherman
    Chief Medical Officer & Executive Vice President
  • Vikram KarnaniVikram Karnani
    President-International, Medical Affairs & EVP
  • Michael A. DesJardinMichael A. DesJardin
    Executive VP-Technical Operations & Quality













HZNP Stock - Frequently Asked Questions

Should I buy or sell Horizon Therapeutics Public stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last year. There are currently 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HZNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HZNP, but not buy additional shares or sell existing shares.
View HZNP analyst ratings
or view top-rated stocks.

What is Horizon Therapeutics Public's stock price forecast for 2023?

11 analysts have issued 1 year price objectives for Horizon Therapeutics Public's stock. Their HZNP share price forecasts range from $71.00 to $144.00. On average, they expect the company's stock price to reach $111.42 in the next year. This suggests a possible upside of 11.4% from the stock's current price.
View analysts price targets for HZNP
or view top-rated stocks among Wall Street analysts.

How have HZNP shares performed in 2023?

Horizon Therapeutics Public's stock was trading at $113.80 at the beginning of the year. Since then, HZNP stock has decreased by 12.1% and is now trading at $100.03.
View the best growth stocks for 2023 here
.

Are investors shorting Horizon Therapeutics Public?

Horizon Therapeutics Public saw a increase in short interest in May. As of May 15th, there was short interest totaling 6,950,000 shares, an increase of 5.8% from the April 30th total of 6,570,000 shares. Based on an average daily trading volume, of 2,290,000 shares, the short-interest ratio is currently 3.0 days.
View Horizon Therapeutics Public's Short Interest
.

When is Horizon Therapeutics Public's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our HZNP earnings forecast
.

How were Horizon Therapeutics Public's earnings last quarter?

Horizon Therapeutics Public Limited (NASDAQ:HZNP) announced its quarterly earnings data on Wednesday, May, 3rd. The biopharmaceutical company reported $0.83 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.17 by $0.34. The biopharmaceutical company had revenue of $832.10 million for the quarter, compared to analyst estimates of $897.06 million. Horizon Therapeutics Public had a trailing twelve-month return on equity of 20.31% and a net margin of 10.40%. The business's revenue for the quarter was down 6.0% compared to the same quarter last year. During the same period last year, the firm earned $1.34 EPS.

What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO?

70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Horizon Therapeutics Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

What is Horizon Therapeutics Public's stock symbol?

Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP."

Who are Horizon Therapeutics Public's major shareholders?

Horizon Therapeutics Public's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.53%), JPMorgan Chase & Co. (2.40%), Farallon Capital Management LLC (2.37%), State Street Corp (2.24%), Renaissance Technologies LLC (1.47%) and Geode Capital Management LLC (1.39%). Insiders that own company stock include Aaron Cox, Andy Pasternak, Barry Moze, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Paul W Hoelscher, Sean M Clayton, Timothy P Walbert, Timothy P Walbert, Vikram Karnani and William F Daniel.
View institutional ownership trends
.

How do I buy shares of Horizon Therapeutics Public?

Shares of HZNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Horizon Therapeutics Public's stock price today?

One share of HZNP stock can currently be purchased for approximately $100.03.

How much money does Horizon Therapeutics Public make?

Horizon Therapeutics Public (NASDAQ:HZNP) has a market capitalization of $22.87 billion and generates $3.63 billion in revenue each year. The biopharmaceutical company earns $521.48 million in net income (profit) each year or $1.59 on an earnings per share basis.

How many employees does Horizon Therapeutics Public have?

The company employs 2,115 workers across the globe.

Does Horizon Therapeutics Public have any subsidiaries?
The following companies are subsidiares of Horizon Therapeutics Public: Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Israel Holding Corp. Ltd, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Services LLC, Horizon Therapeutics Switzerland GmbH, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics, Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, Raptor Pharmaceuticals, River Vision Development Corp., Vidara Therapeutics, and Viela Bio Inc..
Read More
How can I contact Horizon Therapeutics Public?

Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The official website for the company is www.horizontherapeutics.com. The biopharmaceutical company can be reached via phone at (531) 772-2100, via email at investor-relations@horizontherapeutics.com, or via fax at 224-383-3001.

This page (NASDAQ:HZNP) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -